NCT01541007View on ClinicalTrials.gov

A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
DRUG

Cabazitaxel

25 mg/m2 every three weeks

DRUG

weekly cabazitaxel

10 mg/m2 dag 1,8,15,22. Cycle length is 6 weeks

Trial Locations (1)

171 76

Deapartment of Oncology Karolinska University Hospital, Stockholm

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Jeffrey Yachnin M.D., PhD.

OTHER